Discovery of 7-Methoxy-6-[4-(4-methyl-1,3-thiazol-2-yl)-1H-imidazol-5-yl]-1,3-benzothiazole (TASP0382088): A Potent and Selective Transforming Growth Factor-β Type I Receptor Inhibitor as a Topical Drug for Alopecia
スポンサーリンク
概要
- 論文の詳細を見る
7-Methoxy-6-[4-(4-methyl-1,3-thiazol-2-yl)-1H-imidazol-5-yl]-1,3-benzothiazole 11 (TASP0382088) was synthesized and evaluated as transforming growth factor-β (TGF-β) type I receptor (also known as activin receptor-like kinase 5 or ALK5) inhibitor. Compound 11, a potent and selective ALK5 inhibitor, exhibited good enzyme inhibitory activity (IC50=4.8 nM) as well as inhibitory activity against TGF-β-induced Smad2/3 phosphorylation at a cellular level (IC50=17 nM). The introduction of a methoxy group to the benzothiazole ring in 1 and the break up of the planarity between the imidazole ring and the thiazole ring improved the solubility in the lotion base of 11. Furthermore, the topical application of 3% 11 lotion significantly inhibited Smad2 phosphorylation in mouse skin at 8 h after application (71% inhibition, compared with vehicle-treated animals).
著者
-
Ueda Yasuji
Molecular Function and Pharmacology Laboratories, Taisho Pharmaceutical Co., Ltd.
-
Naruse Takumi
Molecular Function and Pharmacology Laboratories, Taisho Pharmaceutical Co., Ltd.
-
Amada Hideaki
Medicinal Chemistry Laboratories, Taisho Pharmaceutical Co., Ltd.
-
Asanuma Hajime
Medicinal Chemistry Laboratories, Taisho Pharmaceutical Co., Ltd.
-
Koami Takeshi
Medicinal Chemistry Laboratories, Taisho Pharmaceutical Co., Ltd.
-
Okada Atsushi
Medicinal Chemistry Laboratories, Taisho Pharmaceutical Co., Ltd.
-
Endo Mayumi
Medicinal Chemistry Laboratories, Taisho Pharmaceutical Co., Ltd.
-
Ikeda Akiko
Molecular Function and Pharmacology Laboratories, Taisho Pharmaceutical Co., Ltd.